Vaccine maker Moderna announced on Thursday that the first adolescents, ages 12 to under 18, in its Phase 2/3 study of coronavirus vaccine candidate mRNA-1273 have been given vaccine doses.
The study, conducted in collaboration with the Biomedical Advanced Research and Development Authority, will evaluate the safety and efficacy of administering two vaccine doses 28 days apart, the announcement said.
Moderna noted that it intends to enroll 3,000 adolescents in the United States.
"We are pleased to begin this Phase 2/3 study of mRNA-1273 in healthy adolescents in the U.S. Our goal is to generate data in the spring of 2021 that will support the use of mRNA-1273 in adolescents in advance of the 2021 school year," Moderna CEO Stéphane Bancel said in the announcement.
"We are encouraged by the interim and primary analyses of the Phase 3 COVE study in adults ages 18 and above and this adolescent study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population. We hope we will be able to provide a safe vaccine to provide protection to adolescents so they can return to school in a normal setting," the announcement continued.